TD Waterhouse Canada Inc. Sells 120,736 Shares of Gilead Sciences, Inc. $GILD

TD Waterhouse Canada Inc. lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 82.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,615 shares of the biopharmaceutical company’s stock after selling 120,736 shares during the period. TD Waterhouse Canada Inc.’s holdings in Gilead Sciences were worth $2,871,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Activest Wealth Management lifted its position in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. GoalVest Advisory LLC boosted its stake in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $27,000. Putney Financial Group LLC increased its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. Finally, Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $126.64 on Friday. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $157.12 billion, a P/E ratio of 25.23, a PEG ratio of 0.81 and a beta of 0.32. The stock’s 50 day moving average is $118.48 and its 200 day moving average is $113.54.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is 48.99%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on GILD. Rothschild & Co Redburn increased their price target on Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Argus increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Truist Financial reaffirmed a “buy” rating and issued a $145.00 price objective (up previously from $127.00) on shares of Gilead Sciences in a research report on Monday, November 3rd. Finally, Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $130.45.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider owned 107,193 shares in the company, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 125,146 shares of company stock valued at $15,148,441 over the last 90 days. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.